CT-based deep learning prediction of complete response in intermediate-stage hepatocellular carcinoma treated with drug-eluting beads transarterial chemoembolization
Authors:
- Jérémy DanaJDJérémy Dana
- Armine VardazaryanAVArmine Vardazaryan
- Benoit GallixBGBenoit Gallix
- Maxime RonotMaxime Ronot
- Jean-Paul MazellierJMJean-Paul Mazellier
- Marlee ParsonsMPMarlee Parsons
- Valérie VilgrainValérie Vilgrain
- Thomas F BaumertTBThomas F Baumert
- Caroline ReinholdCRCaroline Reinhold
- Nicolas PadoyNPNicolas Padoy
- Jules GrégoryJGJules Grégory
Open Access
- 3 January 2025
- journal article
- Published by Oxford University Press (OUP) in BJR|Artificial Intelligence
- Vol. 2 (1)
Abstract
Objectives: To develop a CT-based deep learning (DL) model to predict complete response (CR) to drug-eluting beads-transarterial chemoembolization (TACE) in patients with naive Barcelona Clinic Liver Cancer (BCLC) B hepatocellular carcinoma (HCC). Methods: This dual-centre retrospective study included 93 patients with BCLC B HCC treated with drug-eluting beads-TACE (median size of 40 mm and 37 mm at Institutions 1 and 2). Complete response was defined as per modified Response Evaluation Criteria in Solid Tumours on liver contrast-enhanced CT within 2 months of treatment. A twin-network DL model with spatio-temporal Video Vision Transformer (ViViT) architecture was developed to predict CR using baseline dedicated liver CT. The model was extensively trained/tested based on an 8-fold cross-validation approach with an ensemble technique, a model vote system where the outcome is the average of multiple model predictions. Results: The CR rate was 36% (18/50) and 22% (11/49) at Institutions 1 and 2. The model showed high specificity and AUC, as well as moderate sensitivity and balanced accuracy when using either the late arterial phase (0.91 ± 0.12, 0.86 ± 0.16, 0.43 ± 0.23, and 0.67 ± 0.13, respectively) or the portal venous phase (0.90 ± 0.15, 0.85 ± 0.17, 0.57 ± 0.30, and 0.74 ± 0.16, respectively). Conclusion: The developed CT-based DL model predicted CR to drug-eluting beads-TACE in patients with naive BCLC B HCC with high specificity. It should be refined to improve sensitivity. Advances in knowledge: The study underscores the potential of artificial intelligence in precision medicine in patients with HCC. While the model shows promise, further research with larger datasets and prospective studies is needed to enhance its predictive power and clinical applicability.Keywords
Funding Information
- French National Research Agency within the France 2030 program
This publication has 20 references indexed in Scilit:
- Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialThe Lancet, 2023
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- A quality assessment tool for artificial intelligence-centered diagnostic test accuracy studies: QUADAS-AINature Medicine, 2021
- Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational studyJournal of Hepatology, 2019
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2018
- The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinomaHepatology, 2013
- 3D Slicer as an image computing platform for the Quantitative Imaging NetworkMagnetic Resonance Imaging, 2012
- EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolizationJournal of Hepatology, 2011
- Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolizationCancer Treatment Reviews, 2011